Abstract 4094
Background
In pediatric patients (pts) with localized osteosarcoma, cure rates higher than 60% have been reported. A chemotherapy (CT) regimen frequently suggested as standard in this scenario is the three-drug regimen MAP (methotrexate [MTX], doxorubicin, and cisplatin). However, the addition of MTX remains controversial, especially in adult pts in whom high-grade toxicities are frequent. We aimed to evaluate the outcomes of adult pts with localized osteosarcoma after treatment with CT without MTX.
Methods
A single-center cohort of adult pts with high-grade osteosarcoma treated with CT without MTX was retrospectively evaluated. Pts were treated between 2007 and 2018. Overall survival (OS) was calculated from the date of diagnosis to death. Recurrence-free survival (RFS) was time from diagnosis to recurrence or death. Kaplan-Meier method was used for survival analysis. Prognostic factors were evaluated with Cox regression.
Results
A total of 97 consecutive adult pts with osteosarcoma were studied. Median age was 27 years (range 16 – 69). Primary tumor site was extremity in 79.4% of pts (N = 77), and axial in 20.6% (N = 20). Most pts (N = 61; 63%) presented localized resectable disease, while 36 (37%) had unresectable or metastatic disease. Among pts with localized resectable disease, 56 (91%) pts received neoadjuvant/ adjuvant CT without MTX: 48 (86%) received cisplatin and doxorubicin; 8 (14%) received other combinations of cisplatin, doxorubicin, ifosfamide, and/or etoposide. With a median follow-up of 34 months, 3-year and 5-year RFS rates were 42.4% (IC 95% 28 – 55%) and 37.1% (IC 95% 23 – 50%). 3-year and 5-year OS rates were 81.6% (95% CI, 67% – 90%) and 67.3% (95% CI, 48% – 80%). Median RFS and OS were 31.8 months and not reached, respectively. The only factor associated with OS was the number of neoadjuvant/ adjuvant CT cycles (≥ 6 vs < 6 cycles: HR 0.25, 95% CI 0.07 – 0.83, P = 0.025).
Conclusions
Adult pts with localized osteosarcoma treated with CT without MTX had unfavorable survival outcomes in comparison with the literature for pediatric pts. A number of neoadjuvant/ adjuvant CT cycles of 6 or more was associated with superior OS. Improving therapeutic approaches for adult pts is of utmost importance to achieve better results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience
Presenter: Razia Aslam
Session: Poster Display session 1
Resources:
Abstract
6171 - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies
Presenter: Wojciech Szopa
Session: Poster Display session 1
Resources:
Abstract
4418 - Role of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours.
Presenter: Shweta Wadhwa
Session: Poster Display session 1
Resources:
Abstract
4791 - Tumor related impairments of neurocognitive functions in patients with brain metastases
Presenter: Lei Wen
Session: Poster Display session 1
Resources:
Abstract
5372 - Is radiation therapy influencing Alzheimer’s in Brain and Head and Neck Cancers?
Presenter: Anas Saad
Session: Poster Display session 1
Resources:
Abstract
2329 - Mature Treatment Results of 120 Cases of Acoustic Neuroma Treated with Cyberknife at a single institution.
Presenter: Shawn Malone
Session: Poster Display session 1
Resources:
Abstract
3207 - A phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: the STELLAR study
Presenter: Cyrillo Brahm
Session: Poster Display session 1
Resources:
Abstract
3589 - CNS penetration and Preliminary Efficacy of Sacutizumab Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study
Presenter: Andrew Brenner
Session: Poster Display session 1
Resources:
Abstract
1969 - Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers
Presenter: Takahiro Mimae
Session: Poster Display session 1
Resources:
Abstract
5116 - Characterization of lung tumorspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer
Presenter: Alejandro Herreros Pomares
Session: Poster Display session 1
Resources:
Abstract